Approximately 70% of individuals diagnosed with autism spectrum disorder (ASD) receive at least one psychotropic medication to treat comorbidities. However, the response to treatment with these drugs is far from satisfactory, with 30-50% of treated patients not responding adequately or developing severe and long-lasting side effects. There is strong evidence of the clinical utility of pharmacogenetics for the personalization of antipsychotic and antidepressant treatments in adult populations. However, the use of pharmacogenetic interventions for the personalization of treatment in ASD populations is minimal. The aim of this review is to summarize the findings of pharmacogenetic studies conducted in subjects with ASD and illustrate their utility in the personalization of treatment with psychoactive drugs in this population group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2023-0134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: Aim: To investigate the etiology, pathogenesis, and effectiveness of pharmacotherapy and psychotherapeutic modalities of delusions in Schizophrenia spectrum and other Psychotic Disorders.
Patients And Methods: Materials and Methods: In our study, we included English-language studies from online databases such as Web of Science, Scopus, Google Scholar, PubMed, and the Cochrane Library conducted until January 2024 using the following keywords "delusions", "Schizophrenia spectrum and other Psychotic Disorders", "pharmacotherapy", "psychotherapy", and "antipsychotics". Scientific novelty: There is already published evidence that has studied Schizophrenia spectrum disorders from definition to treatment.
The Neurodiversity Framework in Medicine: On the Spectrum.
Dev Neurobiol
January 2025
Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.
The term "neurodiversity" refers to the natural heterogeneity in human neurological functioning, which includes neurodevelopmental differences and other mental health conditions (e.g., autism spectrum disorder [ASD], attention-deficit hyperactivity disorder [ADHD], dyslexia, bipolar disorder, schizophrenia, and depression).
View Article and Find Full Text PDFCan exercise reduce fatigue in people living with kidney disease?
Curr Opin Clin Nutr Metab Care
January 2025
Institute for Applied Human Physiology, Bangor University, Bangor, UK.
Purpose Of Review: In people living with kidney disease (KD) Fatigue is a whole-body tiredness that is not related to activity or exertion. Often self-reported, fatigue is a common and highly burdensome symptom, yet poorly defined and understood. While its mechanisms are complex, many fatigue-related factors may be altered by exercise and physical activity intervention.
View Article and Find Full Text PDFObjective: To summarize antiretroviral therapy (ART) use in the setting of end-stage kidney disease (ESKD).
Design: Cross-sectional analysis.
Methods: Descriptive analysis of ART regimens and dose of nucleoside/nucleotide reverse-transcriptase inhibitors (NRTI) in people with HIV and ESKD (dialysis, kidney transplantation, or estimated glomerular filtration rate (eGFR) <15 mL/min/1.
Equitable Access to Sports: Youth Gymnastics Coaches' Perceptions on Promoting Inclusivity for Athletes with Autism Spectrum Disorder.
Phys Occup Ther Pediatr
January 2025
Occupational Science and Occupational Therapy, Eastern Kentucky University, Richmond, KY, USA.
Aims: The purpose of the study was to explore youth gymnastics coaches' perceptions on inclusive sports participation following an educational module. The study aims to explore implications for occupational therapy professionals' role in inclusive sports.
Methods: A qualitative descriptive approach was utilized with convenience sampling occurring through online platforms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!